-
Product Insights
Diabetic Peripheral Neuropathy - Drugs In Development, 2024
Empower your strategies with our Diabetic Peripheral Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet; pain or discomfort in the feet or legs, including prickly, sharp pain or burning feet; muscle weakness and loss of muscle tone in the feet and lower...
-
Product Insights
Pompe Disease - Drugs In Development, 2024
Empower your strategies with our Pompe Disease – Drugs In Development, 2024 report and make more profitable business decisions. Pompe disease is an inherited disorder caused by defect in a gene called GAA. The GAA gene is responsible for the production of the GAA enzyme (acid alpha-glucosidase). This enzyme is needed to break down glycogen, a form of sugar stored in muscle cells. When too much glycogen builds up in the muscle cells, the cells become damaged and the muscles cannot...
-
Product Insights
Mitochondrial Diseases - Drugs In Development, 2024
Empower your strategies with our Mitochondrial Diseases – Drugs In Development, 2024 report and make more profitable business decisions. Mitochondrial diseases are a group of genetic conditions that affect how mitochondria function in your body. Mitochondria are the organelles that produce energy for the cell and are found in every cell of the human body except red blood cells. They convert the energy of food molecules into the ATP that powers most cell functions. Mitochondrial diseases can affect almost any part...
-
Product Insights
Homozygous Familial Hypercholesterolemia (HoFH) - Drugs In Development, 2024
Empower your strategies with our Homozygous Familial Hypercholesterolemia (HoFH) – Drugs In Development, 2024 report and make more profitable business decisions. Homozygous familial hypercholesterolemia (HoFH) is a genetic disorder caused by receiving a mutation of the FH gene from both parents. HoFH causes LDL cholesterol level to be very high. Symptoms include xanthelasmas, chest pain, and sores on the toes that do not heal. Treatment includes diet changes and statin drugs. The Homozygous Familial Hypercholesterolemia (HoFH) drugs in development market research...
-
Product Insights
Hypoglycemia - Drugs In Development, 2024
Empower your strategies with our Hypoglycemia – Drugs In Development, 2024 report and make more profitable business decisions. Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia; anxiety; shaking; irritability; and feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity, and cognitive dysfunction. The Hypoglycemia drugs in development market research report...
-
Product Insights
Metabolic Syndrome - Drugs In Development, 2024
Empower your strategies with our Metabolic Syndrome – Drugs In Development, 2024 report and make more profitable business decisions. Metabolic syndrome, also known as insulin resistance syndrome, constitutes a cluster of conditions that collectively heighten the risk of coronary heart disease, diabetes, stroke, and other severe health issues. To be diagnosed with metabolic syndrome, one must exhibit three or more of the following conditions. A significant waistline, termed abdominal obesity or an "apple shape", indicates a higher risk for heart disease...
-
Product Insights
Heterozygous familial hypercholesterolemia (heFH) - Drugs In Development, 2024
Empower your strategies with our Heterozygous familial hypercholesterolemia (heFH) – Drugs In Development, 2024 report and make more profitable business decisions. Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder caused by getting a mutation of the FH gene from an affected parent. Symptoms include xanthesmas, corneal arcus, aortic rupture, and peripheral vascular disease. Risk factors include age, sex, smoking, and hypertension, or associated lipid abnormalities such as low HDL-C levels, high TG levels, or type III dyslipoproteinemia. The Heterozygous familial hypercholesterolemia...
-
Product Insights
Organic Acidemia - Drugs In Development, 2024
Empower your strategies with our Organic Acidemia – Drugs In Development, 2024 report and make more profitable business decisions. Organic acidemia or organic acidurias are a group of inherited metabolic disorders characterized by the accumulation of abnormal organic acid metabolites in the body fluids and tissues. They are caused by a deficiency in an enzyme necessary to break down amino acids, thus causing increased organic acids in body fluids that are then excreted in urine. Vomiting, poor feeding, failure to thrive,...
-
Product Insights
Proliferative Diabetic Retinopathy (PDR) - Drugs In Development, 2024
Empower your strategies with our Proliferative Diabetic Retinopathy (PDR) – Drugs In Development, 2024 report and make more profitable business decisions. Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. PDR occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue, causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy, and tobacco use. Symptoms include spots or dark...
-
Product Insights
Primary Systemic Amyloidosis - Drugs In Development, 2024
Empower your strategies with our Primary Systemic Amyloidosis – Drugs In Development, 2024 report and make more profitable business decisions. Primary systemic amyloidosis is a rare disorder in which abnormal proteins build up in tissues and organs. Clumps of the abnormal proteins are called amyloid deposits. It is plasma-cell dyscrasia characterized by an autonomous proliferation of plasma cells with an overproduction of a monoclonal Ig protein. The final pathway in the development of amyloidosis is the production of amyloid fibrils in...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.